BioSpace News Archive

CD Genomics Optimized Cancer Hotspot Panel Sequencing Service for Cancer-Related Research

Based on rich experience in genomic analysis, CD Genomics has developed a specialized platform for targeted sequencing of cancer-related genes to accelerate research on disease pathogenesis, disease identification, biomarker discovery, targeted drug development, etc.

January 19, 2023
·
2 min read
FDA

Varian Receives Investigational Device Exemption for Cardiac Radioablation Clinical Trial, RADIATE-VT

Varian, a Siemens Healthineers company, announced today that the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) for the pivotal RADIATE-VTTM clinical trial.

January 19, 2023
·
5 min read
Creative Proteomics Lipidomics Upgrades Its Medium-Chain and Long-Chain Fatty Acids Analysis Service

Lipidomics, a platform developed by Creative Proteomics, is dedicated to providing cutting-edge mass spectrometry (MS)-based lipidomic research services for biomedical institutions as well as biotechnological and pharmaceutical companies

January 19, 2023
·
3 min read
Pharm Country

ResoluteAI Launches Clinical Trial Analytics

ResoluteAI, the research platform for science, launched today a Clinical Trials Analytics package that connects clinical trial data with research publications and other datasets.

January 19, 2023
·
2 min read
Biotech Bay

AmMax Bio’s AMB-05X Receives EMA PRIME Designation for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)

AmMax Bio, Inc. (“AmMax”) today announced that the European Medicine Agency (EMA) has granted AMB-05X Priority Medicines (PRIME) designation for the treatment of tenosynovial giant cell tumor (TGCT).

January 19, 2023
·
4 min read
Biotech Beach

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the treatment of opioid overdose.

January 19, 2023
·
4 min read
Business

Procaps Announces Key Changes to the Board of Directors

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced the election of Alberto Eguiguren Correa to its Board of Directors.

January 19, 2023
·
2 min read
Business

Universal Display Corporation Announces Fourth Quarter and Fiscal Year 2022 Conference Call

Universal Display Corporation (Nasdaq: OLED), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced its results for the fourth quarter and full year, ended December 31, 2022, will be released on Thursday, February 23, 2023 after market close.

January 19, 2023
·
3 min read
Genetown

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) today announced the strategic prioritization of clinical development of CYT-0851, an investigational monocarboxylate transporter inhibitor, as a potential combination therapy for the treatment of ovarian cancer.

January 19, 2023
·
7 min read
Drug Development

EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent in Patients Receiving Radiation for Head and Neck Cancers

EpicentRx, a leading edge, clinical stage biopharmaceutical company, announced the publication of Phase 2 results of the PREVLAR trial which demonstrated that RRx-001 protects against severe oral mucositis in patients receiving radiation and chemotherapy for head and neck cancer.

January 19, 2023
·
3 min read